News

Enrollment is now complete in ENHANCE-1, a Phase 3 clinical trial testing Verona Pharma’s experimental inhalation therapy ensifentrine in more than 800 people with chronic obstructive pulmonary disease (COPD). The announcement comes less than five months after Verona completed enrollment in its other Phase 3 trial testing ensifentrine,…

A smartphone app developed by Kaia Health to help people with chronic obstructive pulmonary disease (COPD) manage their breathing difficulties at home, via a digital therapy platform, is now available in North America. The mobile app’s availability followed findings in a clinical trial (DRKS00017275), conducted in Switzerland…

Long-term exposure to air pollution, even at relatively low concentrations, is associated significantly with reduced lung function and may increase the risk of chronic obstructive pulmonary disease (COPD), according to a population-based study in Canada. “Few studies have examined the relationship between air pollution and the lung health of adults…

Note: This story was updated June 6, 2022, to note that the U.S. Food and Drug Administration has assigned an Investigational New Drug application (IND) number to Therapeutic Solutions International experimental JadiCell therapy. The FDA has not yet approved the company’s IND application. The U.S. Food and Drug Administration’s review…

People with chronic obstructive pulmonary disease (COPD) have a higher risk of developing heart disease, even if they only have mild lung function impairments, a study suggests. Also, being male, older, and using statins — a group of medicines commonly prescribed to lower cholesterol levels…

The infection rate of SARS-CoV-2, the virus that causes COVID-19, is 24 times higher in lab-grown airway cells from people with chronic obstructive pulmonary disease (COPD) than in those from healthy people, a study shows. This increased susceptibility to infection, which makes severe outcomes more likely, was associated with…

A first-in-human clinical trial testing the safety and tolerability of EP395, EpiEndo Pharmaceuticals’ experimental treatment for chronic obstructive pulmonary disease (COPD), is now finished. EpiEndo is planning to launch a Phase 2a trial testing EP395 in people with COPD later this year. “The successful completion of this study…

Treatment with immune-suppressing myeloid-derived suppressor cells alongside JadiCell — an investigational stem cell therapy from Therapeutic Solutions International (TSOI) for chronic obstructive pulmonary disease (COPD) — led to more significant reductions in lung damage in mice compared with either treatment alone. Using them together also enhanced pulmonary regeneration…

Therapeutic Solutions International (TSOI) is seeking permission from the U.S. Food and Drug Administration (FDA) to conduct a Phase 1 study of JadiCell, its investigational stem cell therapy, in 10 people with advanced chronic obstructive pulmonary disease (COPD). The request — submitted in the form of an investigational…

The digital Kaia Health mobile app helped people with chronic obstructive pulmonary disease (COPD) to better adhere to a physical activity plan after completing an in-hospital pulmonary rehabilitation program, a study found. Moreover, the patients who used the application for six months also saw…